Department of Error (DOI:10.1016/S0140-6736(09)62162-0);Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis

The Lancet

Volumn 375, Issue 9723, 2010, Pages 1365-1374

  Kahn, Richard ^a   Alperin, Peter ^b   Eddy, David ^b   Borch Johnsen, Knut ^c   Buse, John ^d   Feigelman, Justin ^b   Gregg, Edward ^e   Holman, Rury R ^f   Kirkman, M Sue ^a   Stern, Michael ^g   Tuomilehto, Jaakko ^h   Wareham, Nick J ⁱ  

^a AMERICAN DIABETES ASSOCIATION   (United States)

^b Archimedes   (United States)

^c STENO DIABETES CENTER   (Denmark)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g Mays Cancer Center at UT Health San Antonio   (United States)

^h UNIVERSITY OF HELSINKI   (Finland)

ⁱ ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIABETIC MICROANGIOPATHY; DIABETIC PATIENT; HEART INFARCTION; HUMAN; INCIDENCE; MATHEMATICAL MODEL; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SCREENING; SIMULATION; STROKE; SYMPTOM; UNITED STATES;

EID: 77950930917     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60522-3     Document Type: Erratum

References (45)

1. Cowie C.C., Rust K.F., Byrd-Holt D.D., et al. Prevalence of diabetes and impaired fasting glucose in adults in the US population: National Health And Nutrition Examination Survey 1999-2002. Diabetes Care 29 (2006) 1263-1268
2. Spijkerman A.M., Dekker J.M., Nijpels G., et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screening and patients newly diagnosed in general practice: the Hoorn screening study. Diabetes Care 26 (2003) 2604-2608
3. American Diabetes Association. Screening for type 2 diabetes. Diabetes Care 27 suppl 1 (2004) S11-S14
4. US Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: US Preventive Services Task Force recommendation statement. Ann Intern Med 148 (2008) 846-854
5. Paterson K.R. Population screening for diabetes mellitus. Professional Advisory Committee of the British Diabetic Association. Diabet Med 10 (1993) 777-781
6. CDC Diabetes Cost-effectiveness Group. The cost-effectiveness of screening for type 2 diabetes. JAMA 280 (1998) 1757-1763
7. Hofer T.P., Vijan S., and Hayward R.A. Estimating the microvascular benefits of screening for type 2 diabetes mellitus. Int J Technol Assess Health Care 16 (2000) 822-833
8. Hoerger T.J., Harris R., Hicks K.A., Donahue K., Sorensen S., and Engelgau M. Screening for type 2 diabetes mellitus: a cost-effectiveness analysis. Ann Intern Med 140 (2004) 689-699
9. Goyder E.C., and Irwig L.M. Screening for type 2 diabetes mellitus: a decision analytic approach. Diabet Med 17 (2000) 469-477
10. Glumer C., Yuyun M., Griffin S., et al. What determines the cost-effectiveness of diabetes screening?. Diabetologia 49 (2006) 1536-1544
11. Chen T.H., Yen M.F., and Tung T.H. A computer simulation model for cost-effectiveness analysis of mass screening for type 2 diabetes mellitus. Diabetes Res Clin Pract 54 suppl 1 (2001) S37-S42
12. Icks A., Haastert B., Gandjour A., et al. Cost-effectiveness analysis of different screening procedures for type 2 diabetes: the KORA survey 2000. Diabetes Care 27 (2004) 2120-2128
13. Gillies C.L., Lambert P.C., Abrams K.R., et al. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ 336 (2008) 1180-1185
14. Eddy D.M., and Schlessinger L. Validation of the Archimedes diabetes model. Diabetes Care 26 (2003) 3102-3110
15. Knowler W.C., Barrett-Conner E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
16. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
17. Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications. Diabetes Care 30 (2007) 1638-1646
18. Schlessinger L., and Eddy D.M. Archimedes: a new model for simulating health care systems-the mathematical formulation. J Biomed Inform 35 (2002) 37-50
19. Eddy D.M., and Schlessinger L. Archimedes: a trial-validated model of diabetes. Diabetes Care 26 (2003) 3093-3101
20. Eddy D.M., Schlessinger L., and Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143 (2005) 251-264
21. Kahn R., Robertson R.M., Smith R., and Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care 31 (2008) 1686-1696
22. Archimedes. Archimedes Model. http://www.archimedesmodel.com/ (accessed March 1, 2010).
23. CDC. National Health and Nutrition Examination Survey. http://www.cdc.gov/nchs/nhanes.htm (accessed Feb 26, 2009).
24. Colagiuri S., Cull C.A., and Holman R.R. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UK prospective diabetes study 61. Diabetes Care 25 (2002) 1410-1417
25. Cherry D.K., Hing E., Woodwell D.A., and Rechtsteiner E.A. National Ambulatory Medical Care Survey: 2006 summary. Natl Health Stat Report 3 (2008) 1-39
26. Agency for Healthcare Research and Quality. Medicare expenditure panel survey. http://www.meps.ahrq.gov/mepsweb (accessed April 24, 2009).
27. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
28. Nathan D.M., Buse J.B., Davidson M.B., et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 32 (2009) 193-203
29. Chobanian A.V., Bakris G.L., Black H.R., et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
30. Drugstore.com. The uncommon drugstore. http://international.drugstore.com/default.asp (accessed April 24, 2009).
31. Centers for Medicare and Medicaid Services. Part B extract summary system (BESS) data file. http://www.cms.hhs.gov/NonIdentifiableDataFiles/03_PartBExtractSummarySy stem.asp#TopOfPage/ (accessed April 24, 2009).
32. Centers for Medicare and Medicaid Services. Standard analytical files-LDS. http://www.cms.hhs.gov/LimitedDataSets/12_StandardAnalyticalFiles.asp#To pOfPage/ (accessed April 24, 2009).
33. Centers for Medicare and Medicaid Services. MEDPAR. http://www.cms.hhs.gov/MedicareFeeforSvcPartsAB/03_MEDPAR.asp#TopOfPage/ (accessed April 24, 2009).
34. Centers for Medicare and Medicaid Services. Hospital outpatient regulations and notices. http://www.cms.hhs.gov/HospitalOutpatientPPS/HORD/itemdetail.asp?filterT ype=none&filterByDID=-99&sortByDID=3&sortOrder=descending &itemID=CMS1201238&intNumPerPage=10/ (accessed April 24, 2009).
35. Sullivan P.W., and Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 26 (2006) 410-420
36. Coffey J.T., Brandle M., Zhou H., et al. Valuing health-related quality of life in diabetes. Diabetes Care 25 (2002) 2238-2243
37. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
38. Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
39. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
40. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
41. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352 (1998) 854-865
42. Retnakaran R., Cull C.A., Thorne K.I., Adler A.I., Holman R.R., and UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: UK Prospective Diabetes Study 74. Diabetes 55 (2006) 1832-1929
43. Edelman D., Olsen M.K., Dudley T.K., Harris A.C., and Oddone E.Z. Impact of diabetes screening on quality of life. Diabetes Care 25 (2002) 1022-1026
44. UK Prospective Diabetes Study Group. Quality of life in type 2 diabetic patients is affected by complications but not by intensive policies to improve blood glucose or blood pressure control (UKPDS 37). Diabetes Care 22 (1999) 1125-1136
45. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 20 (1997) 1183-1197